Dr. Barry Dworkin

FDA approval process questioned as it approves new early-stage $56K US/year treatment for Alzheimer’s despite its own panel founding insufficient evidence of efficacy. Only when company changed the study endpoint did it show efficacy compared to placebo.

Medical Mythbusting Commentary for June 8, 2021

[display_podcast]

Source:
In controversial decision, FDA approves first new Alzheimer’s disease drug in nearly 20 years

Related posts:

  1. Alzheimer-affected patients to triple in the next 40 years
  2. Alzheimer drug trial failure offers much to learn and should not be seen as a dead end
  3. Two stories that underlie importance of risk and benefit of using medications
  4. Gender dysphoria in young people is rising—and so is professional disagreement